Lidocaine Patch NovaPlus

/Lidocaine Patch NovaPlus
Lidocaine Patch NovaPlus2018-09-06T09:12:40+00:00

Prescription Drug Name:

Lidocaine Patch NovaPlus

ID:

d9976ebc-9814-47e4-8c88-6eec2bf0e841

Code:

34391-3

DESCRIPTION


id: f86246fc-1fd8-4865-9e41-712f364bfecc
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Lidocaine patch 5% is comprised of an adhesive material containing 5% lidocaine, which is applied to a white non-woven polyethylene terephthalate (PET) material backing and covered with a transparent PET release liner. The release liner is removed prior to application to the skin. The size of the patch is 10 cm x 14 cm. Lidocaine is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4, and has the following structure: Each adhesive patch contains 700 mg of lidocaine (50 mg per gram adhesive) in an aqueous base. It also contains the following inactive ingredients: glycerin, D-sorbitol, propylene glycol, polyvinyl alcohol, urea, sodium polyacrylate, carboxymethylcellulose sodium, gelatin, polyacrylic acid, kaolin, tartaric acid, dihydroxyaluminum aminoacetate, methylparaben, propylparaben, and edetate disodium.

CLINICAL STUDIES


id: 53ec8efa-87a2-43ee-89b8-9bc32923ead9
displayName: CLINICAL STUDIES SECTION
FDA Article Code: 34092-7

Single-dose treatment with lidocaine patch was compared to treatment with vehicle patch (without lidocaine), and to no treatment (observation only) in a double-blind, crossover clinical trial with 35 post-herpetic neuralgia patients. Pain intensity and pain relief scores were evaluated periodically for 12 hours. Lidocaine patch performed statistically better than vehicle patch in terms of pain intensity from 4 to 12 hours. Multiple-dose, two-week treatment with lidocaine patch was compared to vehicle patch (without lidocaine) in a double-blind, crossover clinical trial of withdrawal-type design conducted in 32 patients, who were considered as responders to the open-label use of lidocaine patch prior to the study. The constant type of pain was evaluated but not the pain induced by sensory stimuli (dysesthesia). Statistically significant differences favoring lidocaine patch were observed in terms of time to exit from the trial (14 versus 3.8 days at p-value <0.001), daily average pain relief, and patient’s preference of treatment. About half of the patients also took oral medication commonly used in the treatment of post-herpetic neuralgia. The extent of use of concomitant medication was similar in the two treatment groups.

INDICATION AND USAGE


id: 4a2f08aa-6a37-466b-ad6f-dd013779b991
displayName: SPL UNCLASSIFIED SECTION
FDA Article Code: 42229-5

Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.

CONTRAINDICATIONS


id: 6f654fb9-a7ce-4b09-bf60-4c5417a31364
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Lidocaine patch 5% is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.

OVERDOSAGE


id: 2681bd22-b5c8-4b79-b6e7-341fd5e77934
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

Lidocaine overdose from cutaneous absorption is rare, but could occur. If there is any suspicion of lidocaine overdose (see ADVERSE REACTIONS, Systemic Reactions), drug blood concentration should be checked. The management of overdose includes close monitoring, supportive care, and symptomatic treatment. Dialysis is of negligible value in the treatment of acute overdose with lidocaine. In the absence of massive topical overdose or oral ingestion, evaluation of symptoms of toxicity should include consideration of other etiologies for the clinical effects, or overdosage from other sources of lidocaine or other local anesthetics. The oral LD50 of lidocaine HCl is 459 (346 to 773) mg/kg (as the salt) in non-fasted female rats and 214 (159 to 324) mg/kg (as the salt) in fasted female rats, which are equivalent to roughly 4000 mg and 2000 mg, respectively, in a 60 to 70 kg man based on the equivalent surface area dosage conversion factors between species.

DOSAGE AND ADMINISTRATION


id: e7c68dd3-19ed-4a3f-8806-c7b8c3f426e6
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

Apply lidocaine patch 5% to intact skin to cover the most painful area. Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24-hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner. (See HANDLING AND DISPOSAL) Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination. If irritation or a burning sensation occurs during application, remove the patch(es) and do not reapply until the irritation subsides. When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Lidocaine patch 5% may not stick if it gets wet. Avoid contact with water, such as bathing, swimming or showering.

HANDLING AND DISPOSAL


id: 7da91085-1941-4862-923c-fe89b3f98af2
displayName: SPL UNCLASSIFIED SECTION
FDA Article Code: 42229-5

Hands should be washed after the handling of lidocaine patch 5%, and eye contact with lidocaine patch 5% should be avoided. Do not store patch outside the sealed envelope. Apply immediately after removal from the protective envelope. Fold used patches so that the adhesive side sticks to itself and safely discard used patches or pieces of cut patches where children and pets cannot get to them. Lidocaine patch 5% should be kept out of the reach of children.

HOW SUPPLIED


id: 43b0999a-49ca-4c6c-b7cf-ed1ccf225ea2
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Lidocaine patch 5% is available as the following: Carton of 30 patches, packaged into individual child-resistant envelopes.
NDC 0591-2679-30 
Store at 20o to 25oC (68o to 77oF) [See USP Controlled Room Temperature].  NOVAPLUS Manufactured by:
Actavis Laboratories UT, Inc.
Salt Lake City, UT 84108 USA 
N+ and NOVAPLUS are registered
trademarks of Novation, LLC. 
Revised: February 2015 

PRINCIPAL DISPLAY PANEL


id: 9971e23a-9889-429d-8c0f-f5979acd3a53
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4


NDC 0591-2679-30

Lidocaine
Patch 5%

Each adhesive patch contains:
Lidocaine, 700 mg (50 mg per gram adhesive) in an aqueous base.
Inactive components: non-woven polyethylene terephthalate (PET) backing, glycerin, D-sorbitol, propylene glycol, polyvinyl alcohol, urea, sodium polyacrylate, carboxymethylcellulose sodium, gelatin, polyacrylic acid, kaolin, tartaric acid, dihydroxyaluminum aminoacetate, methylparaben (preservative), propylparaben (preservative), edetate disodium, and a PET release liner.
Usual dosage: For dosage and full prescribing information, read accompanying product information.
Store at 20° to 25°C [see USP Controlled Room Temperature].
WARNING: Keep used and unused patches out of the reach of children, pets and others.

Rx only 

30 Patches

(30 Envelopes Containing 1 Patch Each)

NOVAPLUS®